START is dedicated to the conduct of Phase I Clinical Trials of novel anticancer agents.
With centers located in San Antonio, Texas; Madrid, Spain; and Shanghai, China; START conducts the world’s largest Phase I medical oncology program. Today, more than 50 percent of cancer patients can be cured with conventional treatments – that is, therapies with a proven response rate. However, there are many patients who do not respond to standard treatment and may be eligible for participation in our Phase I clinical trials program.
START is dedicated to developing improved preclinical models and assays to accelerate oncology drug development.
START's preclinical program is unique in that our researchers work alongside leading Phase I clinicians whose clinical experience and collaboration allows us to accelerate the movement of agents through preclinical development and into first in man studies. Contact Preclinical Services Now >
San Antonio 1000 Cancer Genome Project
START proudly supports the San Antonio 1000 Cancer Genome Project. Read more about how you can become involved.